|
Tuesday, November 5, 2019 |
|
Jacobson Pharma Adds Excilor to Its Portfolio to Develop China Market with Vemedia (The Netherlands) |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in research, development, production, marketing and sale of generic drugs and proprietary medicines more info >> |
|
Thursday, October 31, 2019 |
|
雅各臣與建豐胃仙-U成立合資公司 |
從事非專利藥及品牌藥品研發、生產、市場推廣及銷售的領先企業-雅各臣科研製藥有限公司(「雅各臣」或「集團」;股份代號:2633)今天公佈,集團之全資附屬公司Smiley Sun Limited(「Smiley」)與建豐胃仙-U有限公司(「建豐胃仙-U」)訂立合資公司協議(「合資公司協議」)成立一間新公司(「合資公司」) ,並由Smiley及建豐胃仙-U各自擁有50%權益。 more info >> |
|
雅各臣与建丰胃仙-U成立合资公司 |
从事非专利药及品牌药品研发、生产、市场推广及销售的领先企业-雅各臣科研制药有限公司(「雅各臣」或「集团」;股份代号:2633)今天公布,集团之全资附属公司Smiley Sun Limited(「Smiley」)与建丰胃仙-U有限公司(「建丰胃仙-U」)订立合资公司协议(「合资公司协议」)成立一间新公司(「合资公司」),并由Smiley及建丰胃仙-U各自拥有50%权益。 more info >> |
|
Jacobson Pharma Forms Joint Venture with Kin Fung Weisen-U |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaging in the research, development, production, marketing and sale of generic drugs and proprietary medicines more info >> |
|
Tuesday, June 25, 2019 |
|
雅各臣公布二零一九财年全年业绩 |
从事非专利药及品牌药品研发、生产、市场推广及销售的领先企业 ─ 雅各臣科研制药有限公司(「雅各臣」或「公司」;股份代号:2633)今天公布公司及其附属公司(统称「集团」)于截至二零一九年三月三十一日止年度(「二零一九财年」)的全年业绩。 more info >> |
|
雅各臣公佈二零一九財年全年業績 |
從事非專利藥及品牌藥品研發、生產、市場推廣及銷售的領先企業 ─ 雅各臣科研製藥有限公司(「雅各臣」或「公司」;股份代號:2633)今天公佈公司及其附屬公司(統稱「集團」)於截至二零一九年三月三十一日止年度(「二零一九財年」)的全年業績。 more info >> |
|
Jacobson Pharma Announces FY2019 Annual Results |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, today announced its annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2019 (the "FY2019"). more info >> |
|
Wednesday, May 8, 2019 |
|
雅各臣与云南白药集团将继续探讨业务及其他方面合作可行性 |
从事非专利药及品牌药品研发、生产、市场推广及销售的领先企业─ 雅各臣科研制药有限公司(「雅各臣」或「集团」;股份代号:2633)获其股东云南白药控股有限公司(「白药控股」)及云南白药集团股份有限公司(「云南白药集团」,于深圳证券交易所上市)告知,云南白药集团将与白药控股进行吸收合并重组。 more info >> |
|
雅各臣與雲南白藥集團將繼續探討業務及其他方面合作可行性 |
從事非專利藥及品牌藥品研發、生產、市場推廣及銷售的領先企業 ─ 雅各臣科研製藥有限公司(「雅各臣」或「集團」;股份代號:2633)獲其股東雲南白藥控股有限公司(「白藥控股」)及雲南白藥集團股份有限公司(「雲南白藥集團」,於深圳證券交易所上市)告知,雲南白藥集團將與白藥控股進行吸收合併重組。 more info >> |
|
Jacobson Pharma and Yunnan Baiyao Group to Continue Exploring Further Possibilities of Business Cooperation and Other Collaborations |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaging in the research, development, production, marketing and sale of generic drugs and proprietary medicines, has been informed by Yunnan Baiyao Holdings Company Limited1 ("Baiyao Holdings") and Yunnan Baiyao Group Co.,Ltd. more info >> |
|
|
|